When: Close below $81.21 (Bollinger lower band) on rising volume

Then: Secondary invalidation of Hold thesis

When: Quarterly dividend dates

Then: Reinvest $0.76/share dividend

HOLD existing position; do not add exposure until 50 SMA reclaimed at 89.33, MACD turns positive, and September 18th institutional selling absorbed

• Death cross historical comparisons (2015, 2018, 2022) are invalid; today features no Fed cuts priced (96% probability of no cuts in 2026), elevated sticky ten-year yield
• ATR at 1.33 indicates low realized volatility but does not predict direction; volatility compression could precede downside capitulation
• Higher lows from 81.69 (September 28) to 83.47 (October 1) represent only 2.2% range in confirmed downtrend; not equivalent to higher lows in uptrend
• 50 SMA at 89.33 must be reclaimed before interpreting stabilization as reversal
• Total capital raised of 9.3 billion in H1 2026 with 70% YoY equity issuance increase represents a pace, not one-time event; cumulative dilution effect matters
• Forward EPS of 4.92 is analyst estimate subject to revision with faster-than-expected dilution; 18.6% EPS growth not guaranteed
• Fair value calculation is circular; multiple of 17x is not exogenous and will compress with death cross, hostile rates, and deteriorating technicals
• Q3 earnings requires two simultaneous positive outcomes (reaffirm 4.92 EPS and constructive 2027 capex guidance); either could disappoint
• Fed pivot priced at 4% probability (96% odds it does not happen); positioning for cut scenario is low-probability bet
• Risk-reward framing misleading: 80.80 stop is not guaranteed given multiple gap-down episodes; stock has demonstrated it does not respect technical levels
• 89.33 target is 50 SMA in confirmed downtrend, likely rejection point, not breakout level
• Supports existing trader rules (breakout above 89.33 on 15M volume or positive MACD histogram) but would tighten add-on trigger to close above 87.50
• 80.80 failure exposes position to re-test of 2024 lows and potentially much lower; 75 support cited by aggressive analyst is inadequate
• Zero fresh capital at risk until technicals confirm breakdown is over

→ vs aggressive: Historical death cross buying opportunities on dividend aristocrat utilities (2015, 2018, 2022) are not applicable; macro backdrop today features no Fed cuts priced, elevated sticky yields

→ vs aggressive: ATR compression and RSI divergence do not indicate direction; low volatility in broken downtrend is as consistent with downside capitulation as mean reversion

→ vs aggressive: Higher lows from 81.69 to 83.47 in confirmed downtrend are not equivalent to higher lows in uptrend; 50 SMA at 89.33 must be reclaimed

→ vs aggressive: 9.3 billion total capital raised in H1 2026 with 70% YoY equity issuance increase is a pace; cumulative dilution effect on per-share value not addressed

→ vs aggressive: Forward EPS of 4.92 is analyst estimate, not contractual obligation; likely to be revised downward with faster-than-expected dilution

→ vs aggressive: Fair value calculation is circular: 17x multiple on 4.92 EPS assumes today's multiple remains constant, but multiples compress with death cross and hostile rate backdrop

→ vs aggressive: Q3 earnings requires simultaneous reaffirmation of 4.92 EPS and constructive 2027 capex guidance; thesis requires multiple speculative positive outcomes

→ vs aggressive: Fed pivot scenario priced at 4% probability; positioning for cut is low-probability bet, not asymmetric opportunity

→ vs aggressive: Risk-reward math misleading: 80.80 stop not guaranteed given historical gap-down behavior; 89.33 target is 50 SMA in downtrend, likely rejection point

→ vs aggressive: Next support below 80.80 is not 75 but re-test of 2024 lows; aggressive thesis does not adequately price this tail risk

→ vs neutral: Clarity is a process, not a price; framework should size correctly and define exits in advance rather than wait for perfect setup

Maintain HOLD with tactical adjustments: partial add trigger at 85.63 Bollinger band reclaim on rising volume (full add still requires 50 SMA reclaim and 89.33 breakout on 15 million shares), consider 10-15% position trim on relief rally toward 85-86, and secondary invalidation at 81.21 Bollinger lower band daily close regardless of stop price.

• Beta of 0.316 provides structural defensiveness; investors buying SO are buying regulated earnings visibility and 3.64% yield, not beta
• Forward EPS of 4.92 with 17x multiple yielding 83.64 fair value is circular reasoning—the multiple depends on stable technicals to justify the price
• Current macro regime has 96% probability of no rate cuts in 2026 with elevated ten-year yields—fundamentally different from 2015, 2018, and 2022 easing setups
• ATR of 1.33 on $83 stock equals 1.5% daily range; annual yield of 3.64% provides approximately 2.4% annual carry to wait for technical resolution
• Hard stop at 80.80 is reasonable but September 23 gap shows stock does not cleanly respect levels
• Q2 2026 net income up 33% YoY confirms underlying earnings engine running; construction in progress grew from 7.7B to 11.87B YoY
• The conservative analyst's catalyst calendar framing is overstated—the aggressive thesis only needs ONE catalyst (like Q3 earnings reaffirming 4.92 EPS) to trigger reversion, not all catalysts
• Position is 5.6% underwater from 88.50 entry, consuming more risk envelope than at entry; partial trim on relief rally reduces risk without capitulating

→ vs aggressive: Historical death cross comparisons to 2015, 2018, and 2022 are flawed—those episodes all featured dovish Fed pivots, but today has 96% probability of no rate cuts in 2026 with elevated yields, making outcomes dependent on easing Fed impossible to anchor on

→ vs aggressive: Fair value calculation multiplying 4.92 EPS by 17x multiple is circular—the 17x multiple is endogenous to the rate environment and technical setup, so using it to justify price stability is tautological reasoning

→ vs aggressive: ATR compression does not predict direction—it is equally consistent with capitulation lower as with mean reversion higher; presenting one of two equally plausible outcomes as definitive is conviction masquerading as analysis

→ vs conservative: Framing of catalyst calendar as requiring four things to go right is overstated—the thesis only needs one catalyst (Q3 earnings reaffirming 4.92 EPS) to compress multiple risk and trigger reversion; Georgia PSC and Fed pivot are gravy, not requirements

→ vs conservative: Underselling structural defensiveness—beta of 0.316 means SO is already a defensive allocation, and option premium being paid to be long is attractive relative to realized volatility with 2.4% annual carry and hard stop at 80.80

→ vs conservative: Mischaracterizes aggressive analyst's position by treating HOLD as neutral when aggressive analyst is actually arguing not to sell, not to add capital; the trader's existing rules already preclude adding without 15M share volume breakout or positive MACD, which conservative analyst supports